Holistic Treatment for Injection-Related Infections (IRIS Trial)

N/A

Waitlist Available

Research Sponsored by McMaster University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Presenting with a confirmed or suspected injection-related infection (including skin and soft tissue infections, osteomyelitis, infective endocarditis, Hepatitis C, HIV, etc)

Age 16 or older

Timeline

Screening 3 weeks

Treatment Varies

Follow Up within 6 months of initial hospital admission or program enrolment

Awards & highlights

No Placebo-Only Group

Summary

This trial provides a 1-stop shop of care, support & systems navigation for people who inject drugs & experience injection-related infections. It aims to improve access to treatment & reduce ED visits, hospitalizations & deaths.

Who is the study for?

The IRIS program is for individuals in Hamilton, Ontario who use injection drugs and have an infection related to this, like abscesses or heart valve infections. Participants must be 16 or older and able to give informed consent.

What is being tested?

This trial tests a holistic care approach for people with drug-related infections. It provides substance use treatment, infectious disease care, peer support, and help navigating the system without randomizing participants.

What are the potential side effects?

Since this is not a drug trial but rather a service intervention study, traditional side effects are not applicable. However, there may be emotional or social impacts from participating in such comprehensive care programs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have or might have an infection from an injection, including skin, bone, heart infections, Hepatitis C, or HIV.

Select...

I am 16 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ within 6 months of initial hospital admission or program enrolment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~within 6 months of initial hospital admission or program enrolment

This trial's timeline: 3 weeks for screening, Varies for treatment, and within 6 months of initial hospital admission or program enrolment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Secondary study objectives

Completion of intended course of treatment for the injection-related infection

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Intervention groupExperimental Treatment1 Intervention

Participants in the IRIS program will be offered a one-stop, low-barrier combined care model to address their injection-related infections. Specific program components include: (1) Diagnosis and treatment of injection-related infections; (2) Substance use treatment (3) Peer support; and (4) Care coordination/systems navigation.

0 / 2Eligibility criteria met